Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Blinatumomab

Hazard - P - B - T - Risk Exempt

Information

Assessment report

Assessment report for BLINCYTO (blinatumomab), 24 September 2015, EMA/CHMP/469312/2015.

"Blinatumomab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, blinatumomab it is not expected to result in a significant risk to the environment."

Fass environmental information

Fass environmental information for BLINCYTO from Amgen (downloaded 2019-09-04).

Risk

The use of amino acids, proteins and peptides is not expected to have any environmental impact.

Detailed information

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

Author: Health and Medical Care Administration, Region Stockholm